Angiopoietin-like protein 2 and risk of type 2 diabetes in a general Japanese population: The Hisayama study

Diabetes Care

Volumn 36, Issue 1, 2013, Pages 98-100

  Doi, Yasufumi ^a   Ninomiya, Toshiharu ^a   Hirakawa, Yoichiro ^a   Takahashi, Otowa ^b   Mukai, Naoko ^a   Hata, Jun ^a   Iwase, Masanori ^a   Kitazono, Takanari ^a   Oike, Yuichi ^b   Kiyohara, Yutaka ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN LIKE PROTEIN 2; C REACTIVE PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; ANGIOPOIETINS; ASIAN CONTINENTAL ANCESTRY GROUP; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84872012318     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-0166     Document Type: Article

References (15)

1. Kim I, Moon SO, Koh KN, et al. Molecular cloning, expression, and characterization of angiopoietin-related protein. angiopoietin-related protein induces endothelial cell sprouting. J Biol Chem 1999;274:26523-26528
2. Kim I, Kim HG, Kim H, et al. Hepatic expression, synthesis and secretion of a novel fibrinogen/angiopoietin-related protein that prevents endothelial-cell apoptosis. Biochem J 2000;346:603-610
3. Oike Y, Akao M, Kubota Y, Suda T. Angiopoietin-like proteins: potential new targets for metabolic syndrome therapy. Trends Mol Med 2005;11:473-479
4. Tabata M, Kadomatsu T, Fukuhara S, et al. Angiopoietin-like protein 2 promotes chronic adipose tissue in fl ammation and obesity-related systemic insulin resistance. Cell Metab 2009;10:178-188
5. Okada T, Tsukano H, Endo M, et al. Synoviocyte-derived angiopoietin-like protein 2 contributes to synovial chronic inflammation in rheumatoid arthritis. Am J Pathol 2010;176:2309-2319
6. Doi Y, KuboM, Yonemoto K, et al. Fasting plasma glucose cutoff for diagnosis of diabetes in a Japanese population. J Clin Endocrinol Metab 2008;93:3425-3429
7. Genuth S, Alberti KG, Bennett P, et al.; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160-3167
8. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acutephase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997;40:1286-1292
9. Varma V, Yao-Borengasser A, Rasouli N, et al. Muscle in flammatory response and insulin resistance: synergistic interaction between macrophages and fatty acids leads to impaired insulin action. Am J Physiol Endocrinol Metab 2009;296:E1300-E1310
10. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006;116:1793-1801
11. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of infl ammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999;353:1649-1652
12. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM; Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002;51:1131-1137
13. Doi Y, Kiyohara Y, Kubo M, et al. Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: the Hisayama Study. Diabetes Care 2005;28:2497-2500
14. Duncan BB, Schmidt MI. The epidemiology of low-grade chronic systemic inflammation and type 2 diabetes. Diabetes Technol Ther 2006;8:7-17
15. Pearson TA, Mensah GA, Alexander RW; et al Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511